GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • AHMED, SARAH  (1)
  • English  (1)
  • 1
    In: Diabetes, American Diabetes Association, Vol. 73, No. Supplement_1 ( 2024-06-14)
    Abstract: Introduction & Objectives: Efficient automated EMR review methods to identify people with atypical diabetes (DM) for research are lacking. We aimed to develop a novel Python-based Expeditious Program for EMR Review (PEPPER) and assess its efficiency. Methods: We extracted the list of 1660 youth ( & lt;19 yo) with type 2 DM (T2D) seen between 2019-2022 from EMR to identify candidates with A-β+ (autoantibody negative, preserved β-cell function) Ketosis-prone DM (KPD) for enrollment into Rare and Atypical Diabetes Network (RADIANT). We developed PEPPER to identify diabetic ketoacidosis (DKA) occurrence within 6 months (mo) of diagnosis to prioritize individuals for detailed manual chart review for RADIANT eligibility. We also manually reviewed EMR of 100 youth with T2D to identify DKA occurrence within 6 mo of diagnosis without PEPPER for comparison. Results: PEPPER identified 110 youth with T2D who had DKA within 6 mo of diagnosis. Twenty-one met the RADIANT A-β+ KPD criteria. The time spent to identify those with T2D and DKA was significantly shorter with PEPPER compared to manual review (13.4 ± 3.9 vs. 26.6 ± 9.4 seconds, p & lt;0.001), translating to 6.2 vs. 12.3 hours to review 1660 charts with and without PEPPER. Both methods yielded identical results, confirming PEPPER’s accuracy. Conclusion: We developed a novel, efficient and reliable EMR review method that could be used on large cohorts to identify research candidates. Disclosure M. Ahmed: None. E.A. Kubota-Mishra: None. A.F. Siller: None. A.E. Davis: None. I. Migacz: None. S. Sisley: Speaker's Bureau; Rhythm Pharmaceuticals, Inc. J. Faruqi: None. Z.I. Saeed: None. S. Ahmed: None. L.H. Philipson: Research Support; Novo Nordisk, Novo Nordisk Foundation, Dompé, Vertex Pharmaceuticals Incorporated, Imcyse. M.J. Redondo: None. A. Balasubramanyam: None. M. Tosur: None. Funding U54 DK118638 and U54 DK118612 (RADIANT Study Group) and K23-DK129821 (MT)
    Type of Medium: Online Resource
    ISSN: 0012-1797
    Language: English
    Publisher: American Diabetes Association
    Publication Date: 2024
    detail.hit.zdb_id: 1501252-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...